Drug Approval | March 06, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
She was the CEO of Tata Insights and Quants a Division of the Tata Industries Ltd.
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Rocuronium Bromide Injection is a neuromuscular blocking agent
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
The WHO - Global Center for Traditional Medicine will help member countries in taking enabling steps in their countries for strengthen education and practices of traditional mdicine
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
he product will be launched shortly in the US market.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Subscribe To Our Newsletter & Stay Updated
